Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YMYousef MortazaviNANiran AlmudhfarNKNechama Kalter

Discussion

Loading...

Member takes

Overview

Preclinical development demonstrates improved tumor clearance and T-cell longevity in multiple myeloma, suggesting a scalable CAR-T platform.

Key Points

  • Chimeric antigen receptor T cells showed prolonged tumor clearance and enhanced efficacy against multiple myeloma.
  • Cytotoxicity assays revealed superior anti-myeloma activity compared to FDA-approved constructs, with improved durability.
  • Manufacturing under GMP-compatible conditions utilized CRISPR/Cas9 for targeted integration at the TRAC locus.
  • Findings support a first-in-human trial, highlighting the potential for safer, non-viral CAR-T therapies.

Cite This Study

Mortazavi et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db2ehttps://doi.org/10.1182/blood-2025-5958
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Development of a novel CD19/BCMA dual CAR-T for autoimmune diseases2025 · 1 citations
  2. 2Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma2025
  3. 3Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited2025
  4. 4Development of novel MZB1-directed HLA-dependent CAR T cell and CAR enhancer therapy in MM and other B-cell malignancies2025
  5. 5BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial2025 · 1 citations